2023
06 November, 2023
T-knife Therapeutics Announces the Appointment of Simone Silva Steiner, Ph.D., as Chief Technical Operations Officer
27 September, 2023
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
01 June, 2023
T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting
08 February, 2023
T-knife Therapeutics Announces the Appointment of Behzad Kharabi, M.D., as Chief Medical Officer
2022
20 October, 2022
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
05 Jan, 2022
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel
2021
30 Nov, 2021
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors
15 Nov 2021
T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T
04 AUG, 2021
T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer
02 AUG, 2021
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
12 JUL, 2021
T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer